NewIntroducing the StillHer Clarity Kit — the complete cascade protocolExplore the Kit →
SKIN & HAIR • BIOLOGY

Losing Hair on Your Head,
Growing It on Your Chin

The same hormone is doing both. And nobody warned you.

Samantha Jones
Samantha Jones, Research Advocate · Updated April 14, 2026 · 12 min read
Up to 50% of postmenopausal women experience new facial hair growth, with the chin as the most common site.

The same molecule — DHT (dihydrotestosterone) — causes both scalp thinning and facial hair growth simultaneously. Scalp follicles miniaturize in response to DHT. Facial follicles do the opposite: they convert fine vellus hairs into thick, coarse terminal hairs. It is one hormonal shift producing opposite effects in follicles with different androgen receptor profiles. Treatments that block DHT — spironolactone, for example — address both sides of the paradox at once.

There is a particular kind of absurdity that nobody prepares you for. You are standing in front of a mirror, examining a part that is wider than it was six months ago, and then you look down and find a coarse, dark hair on your chin that was not there yesterday. Your scalp is losing what you want. Your face is growing what you do not want. And both are happening at the same time, driven by the same hormonal shift.

Most explanations stop at “androgen dominance” and leave you with the vague impression that androgens are somehow relocating hair from your scalp to your chin, as if they are commuting. They are not. The mechanism is more specific than that — and understanding it changes what you do about it.

~50%of postmenopausal women
experience facial hirsutism
52%of postmenopausal women
have pattern hair loss

The Same Hormone, Two Opposite Effects

When estrogen and progesterone decline during perimenopause and menopause, they stop performing two protective functions at the hair follicle level: estrogen was converting local androgens to estrogen via aromatase, and progesterone was inhibiting 5-alpha reductase (the enzyme that converts testosterone to DHT). With both buffers removed, DHT rises locally — even though circulating androgen levels in most women remain normal. (Blume-Peytavi et al., Br J Dermatol, 2011; PMC review, 2023)

Here is where the paradox takes shape. Androgens do not simply increase or decrease all hair uniformly. They have location-specific effects — determined by the type and sensitivity of the androgen receptors within each follicle.

On Your Scalp

DHT shrinks the follicles

Scalp follicles — particularly at the crown and vertex — express androgen receptors that trigger miniaturization when activated by DHT. The growth phase shortens. The follicle shrinks. Thick terminal hairs become fine vellus hairs. The part widens. The density drops. This is the estrogen-DHT-follicle cascade in action.

On Your Face

Androgens activate the follicles

Facial follicles — especially on the chin, upper lip, and jawline — are programmed to respond to androgens by converting fine vellus hairs into thick, dark terminal hairs. Without estrogen to suppress this response, the relative androgen dominance activates follicles that were previously quiet. The chin hair you found is those follicles doing exactly what androgens tell them to do.

Same hormone shift. Same woman. Two follicle types. Opposite outcomes.

The Body-Hair Dimension Nobody Mentions

There is a third layer to this redistribution that almost no one discusses. As facial hair increases, many women simultaneously lose hair at other androgen-sensitive body sites — underarms, legs, pubic area. Research by Ali and Wojnarowska found that body hair loss significantly correlates with older age and is most frequent at androgen-sensitive sites — the same sites where androgens had previously been maintaining growth. (Ali & Wojnarowska, Br J Dermatol, 2011)

The redistribution is not random. It follows the follicle-type logic precisely: facial follicles are activated by androgens while body-site follicles (which had depended on a specific androgen-estrogen balance) begin to quiet. Your body is not malfunctioning. It is responding to the new hormonal environment with perfect, site-specific consistency.

Your body is not malfunctioning. It is doing exactly what the new hormonal environment is instructing it to do — with perfect, infuriating consistency.

What Treats Both Sides Simultaneously

The paradox has a clinical advantage: because one molecule drives both problems, treatments that block DHT address both sides at once.

Systemic (prescription, addresses both scalp and face)

  • Spironolactone (100–200 mg/day) — blocks androgen receptors, reducing both scalp miniaturization and facial hair stimulation. In a prospective trial, 86.5% of women using minoxidil plus spironolactone showed improvement at 24 weeks versus 55.3% with minoxidil alone. (Liang et al., Front Med, 2022)
  • HRT — restores estrogen and progesterone, rebuilding the protective buffers. Some women see improvement in both scalp density and facial hair reduction, though evidence for facial hair specifically is observational.

For the scalp specifically

  • Minoxidil 5% (topical) — stimulates follicle growth independently of the hormonal pathway. Does not affect facial hair. (Lucky et al., JAAD, 2004)
  • Nutrafol Women’s Balance — targets DHT via saw palmetto. May support both scalp and facial sides through systemic DHT reduction.

For the face specifically

  • Eflornithine cream (Vaniqa) — prescription topical that inhibits ornithine decarboxylase, slowing facial hair growth. Applied twice daily. Results visible in 4–8 weeks; reverses on discontinuation. Does not affect scalp hair.
  • Laser hair removal — targets melanin in the hair follicle. Most effective on dark hair against lighter skin. Requires multiple sessions. Maintenance sessions may be needed as new follicles are activated by ongoing androgen exposure.
  • Electrolysis — the only FDA-classified “permanent” hair removal method. Destroys individual follicles. Time-intensive but definitive for treated follicles.

Full treatment rankings: Hair Loss Treatments for Menopause, Ranked by Evidence

When Facial Hair Growth Warrants Medical Evaluation

Gradual appearance of a few coarse chin or upper-lip hairs during perimenopause and menopause is common and physiological. It does not require medical investigation in most cases. However, certain patterns do warrant evaluation:

  • Rapid onset of coarse hair growth across multiple sites (face, chest, abdomen) over weeks to months
  • Severe hirsutism with accompanying signs: deepening voice, clitoral enlargement, significant acne onset
  • Sudden change well after menopause is established (years postmenopause)

These may indicate an androgen-secreting tumor (ovarian or adrenal) or other endocrine pathology requiring imaging and hormonal workup (testosterone, DHEA-S, prolactin). Gradual, mild facial hair during the menopausal transition is physiology. Sudden, severe, or progressive facial hair postmenopause is a different clinical question. (PMC review, 2023; StatPearls, 2023)

SKIN & HAIR SERIES
Samantha Jones
Samantha Jones, Research AdvocateSamantha is the editorial voice of StillHer. She translates clinical research into plain language for women navigating perimenopause and menopause. She is not a licensed clinician — her authority comes from evidence, not credentials. Read her story.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any treatment. Samantha Jones is a research advocate, not a licensed clinician.

Frequently Asked Questions

The same hormone — DHT (dihydrotestosterone) — causes both. Scalp follicles in androgen-sensitive zones miniaturize when exposed to DHT, producing thinner hair and eventual loss. Facial follicles do the opposite: DHT activates them, converting fine vellus hairs into thick, coarse terminal hairs. During menopause, declining estrogen and progesterone remove protective buffers against DHT, allowing it to act on both follicle types simultaneously. (Blume-Peytavi et al., Br J Dermatol, 2011)
Yes. Research shows that approximately 50% of postmenopausal women experience facial hirsutism, with the chin as the most common site. It is a physiological response to the shift in estrogen-to-androgen ratio, not a sign of disease. However, sudden or severe onset of facial hair growth, especially with other virilization signs, warrants medical evaluation to rule out androgen-secreting tumors. (PMC review, 2023; Blume-Peytavi et al., 2011)
Yes. Spironolactone blocks androgen receptors systemically, reducing both scalp miniaturization and facial hair stimulation simultaneously. HRT restores the estrogen and progesterone buffers that kept DHT in check. Topical treatments like minoxidil (scalp only) or eflornithine cream (face only) target one side of the paradox each. (Liang et al., Front Med, 2022)
Laser hair removal targets melanin in the hair follicle and is most effective on dark hair against lighter skin. Multiple sessions are typically needed. Because menopause continually activates new facial follicles through ongoing androgen exposure, maintenance sessions may be necessary. It treats existing terminal hairs but does not prevent new ones from being activated by DHT.
Body hair at androgen-sensitive sites (underarms, legs, pubic area) depends on a specific androgen-estrogen balance for maintenance. When that balance shifts during menopause, some of these follicles quiet down while facial follicles activate. Research shows body hair loss significantly correlates with older age and is most frequent at androgen-sensitive sites. The redistribution follows the same follicle-type logic as the scalp-face paradox. (Ali & Wojnarowska, Br J Dermatol, 2011)

The StillHer Clarity Kit

The paradox makes sense once you see the full hormonal picture.

The Clarity Kit maps every symptom — scalp, face, and body — to the cascade driving it. One framework. Every change explained.

Get the Clarity Kit — $27